APA (7th ed.) Citation

RJ, M., PB, R., T, P., L, A., JB, H., J, L., . . . TK, C. (2020). Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: Biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature medicine, 26(11), 1733. https://doi.org/10.1038/s41591-020-1044-8

Chicago Style (17th ed.) Citation

RJ, Motzer, et al. "Avelumab Plus Axitinib Versus Sunitinib in Advanced Renal Cell Carcinoma: Biomarker Analysis of the Phase 3 JAVELIN Renal 101 Trial." Nature Medicine 26, no. 11 (2020): 1733. https://doi.org/10.1038/s41591-020-1044-8.

MLA (9th ed.) Citation

RJ, Motzer, et al. "Avelumab Plus Axitinib Versus Sunitinib in Advanced Renal Cell Carcinoma: Biomarker Analysis of the Phase 3 JAVELIN Renal 101 Trial." Nature Medicine, vol. 26, no. 11, 2020, p. 1733, https://doi.org/10.1038/s41591-020-1044-8.